Mental Health Book

Hallucinogen Use Disorders




Synthetic Cannabinoid

Aka: Synthetic Cannabinoid, K2, JWH
  1. See Also
    1. Marijuana
    2. Synthetic Cathinone (Bath Salts)
    3. NBOMe
    4. Chemical Dependency
    5. Substance Abuse Evaluation
    6. Agitated Delirium
  2. Pharmacology
    1. Synthetic Cannabinoids
      1. Produced by spraying herbal plant leaves with cannabinoid receptor agonists
      2. Synthetic agonists are THC-like agents based on one of four synthetic parent agents
      3. Synthetic agonists are small, lipid soluble, non-polar molecules (22 to 26 carbons)
    2. Agents act at two cannabinoid receptors
      1. CB1 - CNS receptors (decrease intracellular cAMP and increase MAP kinase)
        1. Elevates mood and increases feelings of well being
        2. Affects pain tolerance, time perception, memory
      2. CB2 - T Cells, B Cells and Macrophages as well as peripheral nerves
    3. Most agents are pure agonists at cannabinoid CB1 cerebral receptor (contrast with THC as a partial agonist)
      1. Synthetics result in more intense, and unpredictable Intoxication than THC
      2. Synthetic THC lacks the cannabidiol (Antipsychotic, anticonvulsant) effects of Cannabis sativa (Marijuana)
        1. Hence the unpredictable psychotic effects and Seizures with synthetic THC
    4. Typically smoked in pipe or Cigarette paper, but has also been inhaled and ingested
  3. Preparations
    1. Sold in 1-3 gram foil pouches of dried Herbals
      1. Typically labeled as "not for human consumption"
      2. More than 50 distinct products have been identified in the U.S.
      3. Various Herbals and crushed leaves are added for appearance only (drug is dripped onto the leaves)
    2. Street Names
      1. K2
      2. Kronic
      3. Spice
      4. JWH (John W. Huffman)
      5. Legal Marijuana
      6. Fake Weed
      7. Intensely aromatic incense
      8. Cloud-9 (AB-PINACA)
        1. Liquid form vaporized and resulted in multiple hospitalizations in 2014
  4. Symptoms: Sought effects
    1. Euphoria, elevated mood or intense "high"
    2. Uncontrolled laughter
    3. Disinhibition
  5. Signs
    1. Diaphoresis
    2. Hyperreflexia
    3. Nystagmus
    4. Conjunctival injection
  6. Adverse Effects
    1. Neuropsychiatric effects
      1. Confusion
      2. Agitation, irritation or Violent Behavior
      3. Severe anxiety
      4. Memory loss
      5. Loss of consciousness
      6. Generalized Seizures
    2. Acute Psychosis ("Spiceophrenia")
      1. Severe paranoia and Hallucinations (auditory and visual)
      2. May persist for days to months
      3. May occur after a single dose
    3. Gastrointestinal effects
      1. Nausea or Vomiting
      2. Diarrhea
    4. Cardiovascular effects
      1. Palpitations
      2. Heart Rate changes (Tachycardia or Bradycardia)
      3. Blood Pressure changes (Hypertension or Hypotension)
      4. Cardiac ischemia
    5. Endocrine and renal effects
      1. Hypokalemia
      2. Metabolic Acidosis
      3. Hyperglycemia
      4. Acute Kidney Injury
    6. Withdrawal symptoms with regular use
      1. Anxiety, irritability, Insomnia
      2. Chills
      3. Profuse diaphoresis
      4. Tremors
      5. Myalgias
      6. Headaches
      7. Anorexia, Nausea, Vomiting
  7. Labs
    1. Serum Creatinine
    2. Serum Glucose
    3. Creatinine kinase (CK)
    4. Serum Lactic Acid
    5. Serum Troponin
  8. Management
    1. IV crystalloid fluid Resuscitation
      1. Indicated for dehydration
    2. Benzodiazepines
      1. First-line agent
      2. Indicated for agitation
    3. Diphenhydramine
      1. Indicated for Dystonia
    4. Cooling
      1. Indicated for hyperthermia
    5. Antipsychotics (e.g. Zyprexa, Haloperidol)
      1. Indicated for acute Psychosis, esp. refractory to Benzodiazepines
      2. Avoid prophylactically due to theoretical risk of Seizure
  9. Precautions
    1. Agents are unregulated and unpredictable with variable components, potency and toxicity
    2. Acute Psychosis lasting months may occur after only a single dose
  10. Resources
    1. NIH Drug Abuse
    2. DEA K2 or Spice
  11. References
    1. Tomaszewski (2016) Drugs of Abuse, ACEP PEM Conference, Orlando, attended 3/8/2016
    2. Fattore (2011) Front Behav Neurosci 5: 60
    3. Haynes, Meadors and Yuan (2016) Crit Dec Emerg Med 30(2): 3-9
    4. Rosenbaum (2012) J Med Toxicol 8(1): 15–32
    5. Khullar (2014) J Gen Intern Med 29(8):1200-4 +PMID:24553958 [PubMed]

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree